Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients

Inclusion Criteria: Patients (\> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH: * Immobilization * History of VTE * Acute inflammation * Heart failure (NYHA class III or IV) * Respiratory failure Exclusion Criteria: * Indication for LMWH or UFH at therapeutic dosages * Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction) * Contraindication for the treatment with LMWH * Major surgery within the last 4 weeks; minor surgery within the last week * Thrombocytopenia (\< 100.000/μl) * Prolonged prothrombin time * Prolonged activated partial thromboplastin time (aPTT) * History of heparin-induced thrombocytopenia * Bodyweight \< 50 kg or \> 100 kg * Renal insufficiency (creatinine \> 2 mg/dl)